Watch Boston Scientific Senior Manager of Health Economics and Outcomes Research for cardiovascular devices Abimbola Williams, MPH, MS, PhD(c), share a summary of an exciting recent study conducted using Truveta Data, which uncovered disparities among femoropopliteal artery disease patient treatments across social drivers of health factors like geographic location and race. #PeripheralArteryDisease #PAD #FemoropoplitealArteryDisease #BostonScientific #HealthResearch #HealthcareResearch #HealthEconomicsAndOutcomesResearch #HealthOutcomes #HealthcareOutcomes #PatientData #DrugElutingStents #SocialDriversOfHealth #SDOH #SocialDeterminantsOfHealth #HealthEquity #HealthcareDisparities #HealthDisparities #MedicalDisparities #MedicalOutcomes #MedicalData #HealthData #HealthcareData #AI #Innovation
Truveta
Hospitals and Health Care
Seattle area, Washington 68,061 followers
Saving Lives with Data
About us
Truveta is a growing collective of more than 30 health systems, who provide over 18% of the daily clinical care across the United States, with a shared mission of Saving Lives with Data. Trusted by more than 50 leading life science, government, and healthcare organizations, Truveta enables scientifically rigorous research with regulatory-grade data and powerful analytics.
- Website
-
http://www.truveta.com
External link for Truveta
- Industry
- Hospitals and Health Care
- Company size
- 201-500 employees
- Headquarters
- Seattle area, Washington
- Type
- Privately Held
- Founded
- 2020
- Specialties
- Technology, Artificial Intelligence, Health, Data, Health Equity, RWE, RWD, Healthcare Data, and Large Language Model
Locations
-
Primary
Seattle area, Washington, US
Employees at Truveta
Updates
-
With more than 100,000 views in less than three weeks, Truveta Research's recent peer-reviewed publication comparing weight loss among patients taking semaglutide versus tirzepatide is the most popular study in JAMA Internal Medicine this month. 🙌 See what all the excitement is about: https://tr.vet/46l5lJd #tirzepatide #semaglutide #Mounjaro #Ozempic #WeightLoss #WeightLossMedication #WeightLossDrugs #PrescriptionTrends #GLP1s #HealthData #HealthcareData #HealthcareAI #HealthAI #AI #Innovation #HealthInnovation #HealthcareInnovation #MedicalData #MedicalAI #MedicalInnovation #MedicalTechnology #MedTech #EHRData #ElectronicHealthRecords
-
In partnership with STAT News, Truveta Research explored trends in the testing and diagnosis of peripheral vascular disease (#PVD) in US patients 50+. Read the full analysis: https://lnkd.in/g4AQ8sqg #PeripheralVascularDisease #VascularDisease #MedicalDiagnosis #MedicalTesting #HealthTech #HealthData #HealthAI #HealthInnovation #HealthcareTech #HealthcareData #HealthcareAI #HealthcareInnovation #AI #Innovation #MedicalTechnology #MedTech #MedicalData #MedicalAI #MedicalInnovation
Trends in peripheral vascular disease testing and diagnosis
truveta.com
-
Via New York Post: "Overweight or obese adults are three times more likely to shed 15% of their body weight on Mounjaro than Ozempic, according to a study published Monday in the journal JAMA Internal Medicine. “To our knowledge, this study represents the first clinical comparative effectiveness study of tirzepatide and semaglutide in adults with overweight or obesity,” researchers from the health-care analytics firm Truveta wrote in their findings." Read more: https://tr.vet/3Ltjiec #Semaglutide #Tirzepatide #Mounjaro #Ozempic #WeightLossDrugs #WeightLoss #PrescriptionTrends #HealthData #HealthcareData #HealthAI #HealthTech #HealthInnovation #HealthcareTech #HealthcareAI #HealthcareInnovation #AI #Innovation
Ozempic vs. Mounjaro: New study reveals which is better to combat obesity
nypost.com
-
While interest in and prescription rates continue to increase around GLP-1s like #semaglutide and #tirzepatide, access to and use of these medications may be affected by high costs, limited insurance coverage for patients without type 2 diabetes, and medication shortages caused by their surge in popularity. Check out the latest GLP-1 RA prescription and medication dispense trends in Truveta Research's latest monitoring report to learn more: https://tr.vet/3A4VJG7 #Mounjaro #Ozempic #HealthAI #HealthTech #HealthInnovation
GLP-1 prescription trends through June 2024
-
This month, to jointly celebrate Canada Day, America's 4th of July, and France's Bastille Day, members of our senior leadership team doled out ice cream sundaes to Seattle-area employees and family members. 🍨 Thank you to our super scoopers, Fabien Mousseau, Lisa Gurry, Terry Myerson, and Deb Nielsen, and to our Independence Day party organizers, Annie Spencer, Maya Shepherd, Rodolfo Inostroza, Mehraveh Salehi, Shweta Maheshwari, Vijeta Khatri, and Sindhooja M.! 💙🤍❤️
-
Did you know that 1 in 8 men will develop prostate cancer in their lifetime? While most cases are not fatal, prostate cancer does kill ~34,000 Americans every year. For researchers dedicated to advancing treatment for patients with prostate cancer, Truveta provides the most complete, timely, and clean regulatory-grade EHR data for scientifically rigorous research. Truveta Data also includes data from both urology clinics and the rest of the EHR, including oncology data, which is particularly important for prostate cancer research, since most cases are first treated by urologists. Learn more about the prostate cancer data we have available for research: https://tr.vet/4aAWq6N #ProstateCancer #ProstateCancerResearch #CancerResearch #CancerData #HealthData #HealthResearch #HealthcareData #HealthcareResearch #HealthAI #HealthcareAI #MedicalResearch #MedicalData #MedicalAI #MedicalInnovation #EHRData #ElectronicHealthRecords #UrologyData #UrologyClinic #OncologyResearch #OncologyData #AI #Innovation
-
Via CNN: "People taking tirzepatide injections lost more weight and were more likely to reach specific weight loss targets than those taking semaglutide, according to a new study. Researchers from Truveta, a health data analytics company, analyzed electronic health records for more than 18,000 adults, all of whom had overweight or obesity, who were using these medications in the real world between May 2022 and September 2023. The findings were published ... in the JAMA Internal Medicine medical journal." Read more from CNN Health Data Editor Deidre McPhillips: https://tr.vet/4f1Evtj #tirzepatide #semaglutide #Mounjaro #Ozempic #WeightLoss #WeightLossMedication #WeightLossDrugs #PrescriptionTrends #GLP1s #HealthData #HealthcareData #HealthcareAI #HealthAI #AI #Innovation #HealthInnovation #HealthcareInnovation #MedicalData #MedicalAI #MedicalInnovation #MedicalTechnology #MedTech #EHRData #ElectronicHealthRecords
Mounjaro leads to significantly more weight loss than Ozempic, study suggests | CNN
-
This week in USA TODAY: ""As we've tracked GLP-1 use over the last couple of years, we've just seen these dramatic increases of use," said Tricia Rodriguez, who led the study for Truveta Research, and both drugs are "really revolutionizing the treatment of both diabetes and obesity."" Learn more about our GLP-1 comparative effectiveness study, which was recently published in JAMA Internal Medicine: https://tr.vet/4czuwKl #GLP1 #Semaglutide #Tirzepatide #WeightLoss #WeightLossDrugs #PeerReviewed #JAMA #ResearchPublication #HealthData #HealthTech #HealthcareData #HealthcareTech #PrescriptionTrends #PrescriptionData #MedicalData #MedicalTechnology #MedTech #JAMAInternalMedicine #RealWorldData #RealWorldEvidence #AI #HealthAI #HealthcareAI #MedicalAI #Innovation #HealthInnovation #HealthcareInnovation #MedicalInnovation
Ozempic v. Mounjaro? There's a clear winner for weight loss, study finds.
usatoday.com